NCT05135364

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Hepatic Artery Infusion Chemotherapy (HAIC) Combined With Camrelizumab and Tyrosine Kinase Inhibitor for Unresectable Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization (TACE) Failure: a Single-arm and Open-label Prospective Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Yue Han · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research. In this single-arm, open-label, prospective study, for those patients with unresectable primary HCC, in the case of failure of TACE treatment, the combination of HAIC, TKI and immunotherapy is expected to bring new breakthroughs.

Conditions

• Unresectable Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab	Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
DRUG	HAIC	A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks
DRUG	TKI	Lenvatinib or Regorafenib

Timeline

• Start date: 2021-11-05
• Primary completion: 2022-10-05
• Completion: 2024-12-05
• First posted: 2021-11-26
• Last updated: 2021-11-26

Locations

1 site across 1 country: China